JW Jungwoo Pharmaceutical Reveals Preclinical Results of Hair Loss Treatment 'JW0061' at International Wnt Conference
[Asia Economy Reporter Lee Gwan-joo] JW Pharmaceutical announced on the 31st that it will present the preclinical results of the Wnt-targeted alopecia treatment 'JW0061' in a poster session at the 'Wnt 2022' conference to be held in Japan on the 15th of next month.
The Wnt conference is a platform where leading scholars and researchers worldwide in the field of 'Wnt signaling' exchange the latest insights and research findings. This year marks the 40th anniversary of the discovery of the Wnt protein, and the conference will be held in person for the first time in three years.
At this conference, JW Pharmaceutical will unveil for the first time the newly identified mechanism of action (MoA) of JW0061 and the efficacy evaluation results from animal models tested with clinical formulations. This is the first time a domestic pharmaceutical biotech company has presented research results of a new drug candidate at the international Wnt conference.
JW0061 is a first-in-class innovative drug candidate that activates the Wnt signaling pathway, which decreases during the progression of alopecia, promoting the differentiation and proliferation of hair follicle stem cells and cells involved in hair growth. JW Pharmaceutical plans to grasp the overall research trends of its Wnt-targeted new drug pipeline, including the presentation of JW0061 research results. Additionally, it aims to secure opportunities for open innovation with global clinical researchers.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Park Chan-hee, CTO of JW Group, stated, "From a biological perspective, the Wnt signal is a representative signaling system that affects numerous diseases related to regeneration, cancer, and immunity," adding, "At this conference, we will showcase JW's accumulated R&D competitiveness in the Wnt field and engage in diverse discussions with world-renowned researchers to advance our new drug pipeline."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.